07 feb: Fynske Bank A/S: Medarbejdervalg til Fynske Banks bestyrelse
08 feb: Zealand rapporterer royaltyindtægter for Lyxumia® i 4. kvartal 20..
08-02-2017 07:38:45

Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer

Relateret indhold
29 mar - 
Genmab dropper nu også nyheder på dansk
29 mar - 
Aktier/åbning: Mærsk trækker eliteindeks ned mens Carls..
29 mar - 
Aktier/tendens: Vestas kan komme i fokus i lysegrønt ma..
Relateret debat
08:28 - 
solsen:   "Man starter ikke et forsøg op, h..
07:52 - 
Janssens:   http://medwatch.dk/secure/Medicinal___..
07:47 - 
Nyt forsøg under opstart, taget fra proinvestor...

Company Announcement

  • Judith Klimovsky, MD, appointed as Executive Vice President and Chief Development Officer (CDO)

  • CDO joins Genmab’s current Executive team of CEO and CFO

  • Dr. Klimovsky to start at Genmab on February 13, 2017 

Copenhagen, Denmark; February 8, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer (CDO). Dr. Klimovsky will lead the company’s global product development activities and will join the Executive team of Chief Executive Officer, Dr. Jan van de Winkel and Chief Financial Officer, David Eatwell. This appointment reflects Genmab’s decision to strengthen both the leadership structure and global organization as the company develops into a strong, sustainably profitable international biotechnology company. Dr. Klimovsky will be responsible for Genmab’s product development strategy in line with the company’s corporate strategy and the 2025 Vision. Dr. Klimovsky has had a distinguished career in drug development, most recently serving as Senior Vice President and Global Head, Oncology Clinical Development, at Novartis.  She is a hematologist by training with extensive experience in various roles at BMS, Merck and Novartis, as well as having experience in hematology clinical practice. Dr. Klimovsky has broad expertise in Phase I-IV drug development and in medical affairs. She has strong leadership skills and has been instrumental in the development of several key cancer drugs.

“We are very pleased to welcome Judith to Genmab. She has a strong  track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future on the road to becoming a sustainably profitable biotech company,” said Jan van de Winkel, PhD, Chief Executive Officer of Genmab. “With Judith heading our product development efforts we will be able to bring forward truly differentiated products that have the potential to transform the treatment of cancer and provide great benefits to patients and their families in the future.” 

“I am very much looking forward to joining Genmab at this exciting time in the company’s development. Having watched Genmab’s development in recent years, I have been impressed by the company’s  science-based approach, world-class antibody skills, robust product pipeline and competencies in drug development, and I’m eager to start working with the team and state-of-the art portfolio,” said Dr. Judith Klimovsky, new Chief Development Officer at Genmab. 

Dr. Klimovsky will join Genmab on February 13, 2017 and will be based at the company’s Princeton, United States location, whilst travelling regularly to the company’s locations in Copenhagen, Denmark and Utrecht, The Netherlands.

About Judith Klimovsky, MD

Dr. Klimovsky comes from a role as Senior Vice President and Global Head, Oncology Clinical Development at Novartis. She is a recognized drug development leader in the pharmaceutical industry and has previously served in senior roles at Merck and Bristol-Meyers Squibb. Dr. Klimovsky has also held positions in clinical practice in Buenos Aires, Argentina.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 04

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Bredgade 34E

1260 Copenhagen K

Denmark

Vedhæftet fil: 04 CA_CDO_uk_080217.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 mar
GEN
http://finans.dk/erhverv/ECE9448096/amerikansk-storinvestor-genmab-er-et-attraktivt-opkoeb-for-de-st..
4
26 mar
GEN
Solide kursstigninger er ikke at kimse af :-) Genmab har haft overskud i flere år og bruger deres o..
3
24 mar
GEN
du mener helt seriøst at Genmab har et efterslæb til C20........
3
07:52
GEN
Janssens:   http://medwatch.dk/secure/Medicinal___Biotek/article9465660.ece   Sklerose - Roche først..
2
07:47
GEN
Nyt forsøg under opstart, taget fra proinvestor.   https://clinicaltrials.gov/ct2/show/NCT03095118?t..
2
29 mar
GEN
Den tekniske konsolidering ser ud til at være overstået. Bunden er dobbelt testet i området 1390 og ..
2
26 mar
GEN
enig. Os fint at de benytter overskuddet til at fremskynde pipeline. 
2
26 mar
GEN
Jeg er godt tilfreds. Små 3000% de sidste fem år. Så pyt med et par kroner i udbytte.  
2
24 mar
GEN
Rising wedge identificeret som indikere kurs mod modstanden i 1488 inden for den naeste uges tid.
2
08:28
GEN
solsen:   "Man starter ikke et forsøg op, hvis der ikke er faglig begrundelse for at midlet har virk..
1

Vestas får tre ordrer i Kina - NY

29-03-2017 14:36:33
Vestas har fået tre vindmølleordrer til Kina, som alle er annonceret onsdag eftermiddag.Det danske vindmølleselskab skal levere møller til et projekt på 48 megawatt (MW) i Shandong-provinsen, til et 55 MW-projekt et uspecificeret sted i landet og til et andet 48 MW-projekt i Hebei-provinsen.Det fortæller Vestas i tre separate meddelelser.Det første projekt består af 22 V110-møller, der har en nomi..

Aktier/åbning: Mærsk trækker eliteindeks ned mens Carlsberg stiger

29-03-2017 09:36:06
Aktierne i A.P. Møller-Mærsk ligger omkring 150 kr. nede fra åbningen af aktiemarkedet onsdag - og det er lig det udbytte, der fragår aktierne. B-aktien falder med 1,1 pct. til 11.300 kr., mens A-aktien er 1,4 pct. nede i 10.880 kr.Samlet havde eliteindekset hikke fra morgenstunden - men efter 20 minutters handel har minusset bidt sig fast, og eliteindekset falder med 0,4 pct. til indeks 1069,4. D..

Aktier/tendens: Vestas kan komme i fokus i lysegrønt marked

29-03-2017 08:44:42
En større amerikansk satsning på olie og kul kan sætte Vestas i fokus fra morgenstunden, i et marked der ser ud til at åbne i plus.Præsident Donald Trump underskrev tirsdag et dekret om at tilbagerulle centrale dele af sin forgængers, Barack Obamas, klimalovgivning. Og Trump vil blandt andet fjerne et af Obamas tiltag, Clean Power Plan, fordi det ifølge dem er en hindring for olieboring og kulmine..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Vestas kan komme i fokus i lysegrønt marked
2
Vestas får tre ordrer i Kina - NY
3
Aktier/middag: Fransk storbank pifter efter Carlsberg - Pandora bakker
4
Genmab dropper nu også nyheder på dansk
5
Novo genindsender registreringsansøgning for Fiasp i USA - NY

Relaterede aktiekurser

Genmab A/S 1.427,00 0,0% Aktiekurs uændret
Genmab AS DKK1 200,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. marts 2017 08:45:23
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB1 - 2017-03-30 08:45:23 - 2017-03-30 08:45:23 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x